Advertisement
Singapore markets close in 22 minutes
  • Straits Times Index

    3,175.14
    +3.21 (+0.10%)
     
  • Nikkei

    40,003.60
    +263.20 (+0.66%)
     
  • Hang Seng

    16,529.48
    -207.62 (-1.24%)
     
  • FTSE 100

    7,728.17
    +5.62 (+0.07%)
     
  • Bitcoin USD

    64,041.00
    -3,694.43 (-5.45%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,149.42
    +32.33 (+0.63%)
     
  • Dow

    38,790.43
    +75.63 (+0.20%)
     
  • Nasdaq

    16,103.45
    +130.25 (+0.82%)
     
  • Gold

    2,153.60
    -10.70 (-0.49%)
     
  • Crude Oil

    82.52
    -0.20 (-0.24%)
     
  • 10-Yr Bond

    4.3400
    0.0000 (0.00%)
     
  • FTSE Bursa Malaysia

    1,546.97
    -6.67 (-0.43%)
     
  • Jakarta Composite Index

    7,352.99
    +50.54 (+0.69%)
     
  • PSE Index

    6,848.43
    -4.86 (-0.07%)
     

Analysts Are Bullish on Viking Therapeutics Stock

Analysts Are Bullish on Viking Therapeutics Stock

Viking Therapeutics’ (VKTX) stock price rose ~101% on May 31 following the successful trial results of Madrigal Pharmaceuticals’ (MDGL) NASH drug. Madrigal Pharmaceuticals’ drug has a similar mechanism of action as Viking Pharmaceuticals’ NASH drug. In this part, we’ll discuss Wall Street analysts’ recommendations for Viking Therapeutics stock in the next 12 months.